This HTML5 document contains 168 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n11http://dx.doi.org/10.1161/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36836404
rdf:type
wikibase:Item
schema:description
scientific article published on December 2015 artikel ilmiah vědecký článek vitskapeleg artikkel наукова стаття, опублікована в грудні 2015 2015년 논문 ডিসেম্বর ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artikulong pang-agham scientific article published on December 2015 научна статия 2015年论文 2015年論文 bilimsel makale naučni članak article scientific επιστημονικό άρθρο vetenskaplig artikel artículu científicu espublizáu en 2015 2015年論文 artigo científico 2015年论文 scienca artikolo مقالة علمية نشرت في ديسمبر 2015 2015年論文 articol științific บทความทางวิทยาศาสตร์ научни чланак tudományos cikk articolo scientifico artikull shkencor tieteellinen artikkeli מאמר מדעי scientific article published on December 2015 wissenschaftlicher Artikel 2015 nî lūn-bûn 2015年论文 мақолаи илмӣ bài báo khoa học სამეცნიერო სტატია 2015年论文 artículo científico publicado en 2015 wetenschappelijk artikel vedecký článok научная статья article científic article scientifique 2015年论文 2015年論文 artigo científico videnskabelig artikel artykuł naukowy 2015年論文 vitenskapelig artikkel научни чланак 2015年の論文 artigo científico 2015年论文 teaduslik artikkel
p:P577
wds:Q36836404-288897E8-3EA7-41CF-9EA4-0CE20BAE5750
wdt:P577
2015-12-01T00:00:00Z
p:P2860
wds:Q36836404-08E37B96-78B7-4EAE-84F0-F849BF5B4147 wds:Q36836404-164B1553-C023-4943-989D-7D42CF2A75CC wds:Q36836404-1F2A83EB-318F-4CED-9B32-F895E03EEDAB wds:Q36836404-223B6936-BDCB-4C86-865C-4A1700281A38 wds:Q36836404-3D65282B-71DC-46DF-8BDB-637A2053C80F wds:Q36836404-41C6E44C-2EBA-4A78-A929-43CC6328FF8F wds:Q36836404-43D643FF-E7A6-4142-9C79-87C7693DD0E6 wds:Q36836404-4C527886-8AB0-496B-8086-99FA98048A70 wds:Q36836404-5B65E3A3-3960-46F0-88BB-7C23FAA9A3DB wds:Q36836404-636B5EE4-95B3-4F18-96EE-F5EF47A14DC4 wds:Q36836404-64C7D79E-498F-4479-99B5-1E7D4E48850B wds:Q36836404-6C28481F-168B-49E6-A0E1-2F3B19A7A603 wds:Q36836404-78AD0252-4205-416F-99D9-B45EBFBF37B9 wds:Q36836404-7A09AEC2-9FCE-476D-A540-C9DAACCA6C7F wds:Q36836404-81A2089E-0572-4D9D-84EA-21B6AF2F6775 wds:Q36836404-8E9BA1F9-27A3-4827-A0FF-F27B546D2203 wds:Q36836404-9C31364D-A129-41AA-8C1C-B5E63E7F7887 wds:Q36836404-B17BA447-848B-4FBD-A581-C80016FA840C
wdt:P2860
wd:Q40763495 wd:Q29617563 wd:Q79749745 wd:Q35088124 wd:Q81670366 wd:Q29614696 wd:Q50723295 wd:Q74648389 wd:Q46686096 wd:Q72030226 wd:Q35003773 wd:Q28176992 wd:Q28201331 wd:Q56620375 wd:Q38483232 wd:Q29028208 wd:Q28256895 wd:Q43138658
p:P2093
wds:Q36836404-A11B83FC-CAE5-4A05-B1E2-E3D006AEEE7A wds:Q36836404-868C421A-9225-4298-B40C-429EEA63A525 wds:Q36836404-564DE425-3410-4E6F-8118-29A1B20BC1A0 wds:Q36836404-7FE8C2FF-82EB-4C5B-8239-ADE921A3786A
wdt:P2093
Basil S Lewis M Cecilia Bahit Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators Cetin Erol
rdfs:label
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
skos:prefLabel
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
schema:name
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
p:P50
wds:Q36836404-E022122C-F961-4A8E-B031-183D3CC6E007 wds:Q36836404-F226E0CF-1BE1-417F-B427-A895B4279EBC wds:Q36836404-F7225798-5269-4710-BA45-5F8C452005DE wds:Q36836404-390063A7-1ABC-4388-ADF5-608931B8FDFF wds:Q36836404-0BCDB3DE-4980-458C-97E3-918223C18546 wds:Q36836404-0D55E2FB-5AA4-4322-9320-30F374765272 wds:Q36836404-BE4C09D5-2570-4E08-8F35-889D07A7C5B1 wds:Q36836404-C552C2DE-6BDE-45CB-BF07-F5C44518254D wds:Q36836404-D0204153-F092-4E9C-9FC6-C7E62AD8F666 wds:Q36836404-BD24C3E8-7A6A-4199-A585-95A8B4D449FB wds:Q36836404-A196FC3B-A948-4EE6-9415-D090B3EA884D wds:Q36836404-8CC23347-B9E6-4348-B4EF-91331A497368 wds:Q36836404-8355E035-39E5-41B3-939B-97A5533262E5 wds:Q36836404-613A03FE-DC70-4B6B-AB1A-A59C646720AA wds:Q36836404-5DB23DDE-9668-4DED-9E24-D0B62B6014E9
wdt:P50
wd:Q100694590 wd:Q114304484 wd:Q97903767 wd:Q43198009 wd:Q114740056 wd:Q110877755 wd:Q78700420 wd:Q67220498 wd:Q87797284 wd:Q120703226 wd:Q6230815 wd:Q114427074 wd:Q62050240 wd:Q101560035 wd:Q90906040
p:P1476
wds:Q36836404-30BE4CD6-AF39-4F2C-921A-793187DD840E
wdt:P1476
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
p:P31
wds:Q36836404-BD47A38C-7602-4FA8-A21F-EDBF80FF88C5
wdt:P31
wd:Q13442814
p:P921
wds:Q36836404-85A0F0FE-EDAB-4379-9FFF-82486D8E5070 wds:Q36836404-746D0F00-B1F5-4773-9B8F-4C6E3D69354D wds:Q36836404-32229B13-E388-448A-A679-898F422FC437
wdt:P921
wd:Q414462 wd:Q891391 wd:Q815819
p:P698
wds:Q36836404-FA69390D-9AF1-491D-A383-00272ED2EA2E
wdtn:P698
n12:26627878
wdt:P698
26627878
p:P1433
wds:Q36836404-A747845B-4C90-4618-9806-64384F54DD2B
wdt:P1433
wd:Q19880670
p:P433
wds:Q36836404-8639CBAC-ACE0-4341-94B4-A164229C2C58
p:P478
wds:Q36836404-A28AB20D-47ED-4D56-BEE8-579CFEFFD2EA
wdt:P433
12
wdt:P478
4
p:P356
wds:Q36836404-83A63076-65C2-4BCB-9BBF-DF2C38664992
wdtn:P356
n11:JAHA.115.002015
wdt:P356
10.1161/JAHA.115.002015
p:P932
wds:Q36836404-B9F9414C-73E3-490F-947A-1E8D51C8E2CA
wdt:P932
4845276